Latest Developments in Global Point Of Care Hba1c Testing Market

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Latest Developments in Global Point Of Care Hba1c Testing Market

  • Healthcare
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • In February 2024, HemoCue has partnered with Novo Nordisk to enhance point-of-care diagnostic testing for children with type 1 diabetes in low- and middle-income countries. The collaboration will deploy HemoCue HbA1c 501 Systems across 30 countries, aiming to improve diabetes management and reach 100,000 children by 2030
  • In January 2024, Roche announced the acquisition of LumiraDx's point-of-care testing technology for USD 295 million, with an additional investment of up to USD 55 million to support Lumira's technology platform until the deal is finalized
  • In April 2023, FIND partnered with Abbott, i-SENS Inc., and Siemens Healthineers to provide discounted point-of-care HbA1c test kits for low- and middle-income countries, focusing on improving diabetes diagnosis and management in underserved regions
  • In November 2022, LumiraDx expanded the commercial reach of its HbA1c test, aiming to address diabetes management needs in various care settings. The test, run on the LumiraDx Platform, offers rapid results to support screening and monitoring, potentially improving patient outcomes
  • In May 2022, Labcorp introduced an at-home collection kit for diabetes risk testing using a new device from Weavr Health. This initiative provides convenience and accessibility, enabling individuals to monitor their health status from home

Frequently Asked Questions

The market is segmented based on Global Point-of-Care Hba1c Testing Market Segmentation, By Product (Instruments and Consumables), Technology (ION– Exchange HPCL, Enzymatic Assay, Affinity Binding Chromatography, and Turbidimatric  Inhibition Immunoassay), End-Users (Hospitals, Clinics, Ambulatory Surgery Centres, and Others) – Industry Trends and Forecast to 2032 .
The Global Point Of Care Hba1c Testing Market size was valued at USD 670.17 USD Million in 2024.
The Global Point Of Care Hba1c Testing Market is projected to grow at a CAGR of 5.59% during the forecast period of 2025 to 2032.
The major players operating in the market include Bio Rad laboratoriesInc. , Arkray INC, A menarini group,F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH , Hemocue Ab, Trinity Biotech , Pts Digonstic, Siemens healthcare gmbh, Alera inc, Danaher, Sugentech,Tech inc, Getein biotech I.N.C, Bio Merieux India Pvt ltd, EKF Diagnostic.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.